Boustead client Avalon GloboCare ("AVCO”) rings NASDAQ closing bell
Boustead Securities client Avalon GloboCare Corp. (NASDAQ: AVCO), one of the leading global developers of cell-based technologies and therapeutics, rings The Nasdaq Stock Market Closing Bell at the Nasdaq MarketSite in Times Square today at 4:00 PM Eastern time, Monday, January 7, 2019. A live webcast of The Nasdaq Stock Market Closing Bell ceremony will be available at: https://new.livestream.com/nasdaq/live.
Avalon GloboCare Corp's common stock commenced trading on the NASDAQ Capital Market (“NASDAQ”) last November. Over the past 13 months, Boustead served as placement agent and underwriter for private and registered offerings totaling USD$12.6 million.
David Jin, M.D., Ph.D., President and CEO of Avalon GloboCare, stated, “We are honored to ring the closing bell at the Nasdaq MarketSite in celebration of our recent listing. We are rapidly advancing a variety of cell-based therapies, particularly within the field of CAR-T cell therapy, while leveraging our proprietary exosome technology platform and aggressively expanding within the regenerative medicine market. I would like to thank our employees, investors and partners for all the ongoing support, which has been invaluable to our success, and we look forward to driving value for shareholders in the months and years ahead."
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high impact, transformative cell-based /technologies and their clinical applications, as well as healthcare facility management through its core platforms, namely "Avalon Cell" and "Avalon Rehab." In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance their clients' growth, development, as well as competitiveness in both domestic and global healthcare markets. Avalon also engages in the management of stem cell banks and specialty clinical laboratories. Through its U.S. subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon aims to further establish our leading roles in the fields of CAR-T therapy, liquid biopsy, precision medicine and regenerative medicine.
About Boustead Securities, LLC
Member: FINRA/SIPC Boustead Securities, LLC is an investment banking firm that advises clients on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions. Our core value proposition is our ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States and around the world, Boustead's team moves quickly and provides a broad spectrum of sophisticated financial advice and services.
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.